Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies

PURPOSE: To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models. METHODS: We established 12 PDX from BRAF inhibitor progressed melanoma patients. Following expansion, PDX were analyzed using targeted sequencing...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Krepler, Clemens, Xiao, Min, Sproesser, Katrin, Brafford, Patricia, Shannan, Batool, Beqiri, Marilda, Liu, Qin, Xu, Wei, Garman, Bradley, Nathanson, Katherine L., Xu, Xiaowei, Karakousis, Giorgos, Mills, Gordon B., Lu, Yiling, Ahmed, Tamer A., Poulikakos, Poulikos I., Caponigro, Giordiano, Boehm, Markus, Peters, Malte, Schuchter, Lynn M., Weeraratna, Ashani T., Herlyn, Meenhard
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4818716/
https://ncbi.nlm.nih.gov/pubmed/26673799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1762
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki